FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Biochemical analyses provide an answer to the question of how the gut bacterium Morganella morganii might contribute to some ...
Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback